atect Inkomsten in het verleden
Verleden criteriumcontroles 0/6
atect's earnings have been declining at an average annual rate of -13.7%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 1.5% per year.
Belangrijke informatie
-13.7%
Groei van de winst
-13.8%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 32.0% |
| Inkomstengroei | 1.5% |
| Rendement op eigen vermogen | -15.8% |
| Nettomarge | -8.8% |
| Volgende winstupdate | 08 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe atect geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3,199 | -280 | 1,172 | 140 |
| 31 Mar 24 | 3,175 | -244 | 1,173 | 140 |
| 31 Dec 23 | 3,199 | 113 | 1,122 | 169 |
| 30 Sep 23 | 3,218 | 164 | 1,076 | 169 |
| 30 Jun 23 | 3,073 | 180 | 1,034 | 169 |
| 31 Mar 23 | 2,961 | 158 | 1,025 | 169 |
| 31 Dec 22 | 2,944 | 147 | 1,001 | 196 |
| 30 Sep 22 | 2,907 | 156 | 995 | 196 |
| 30 Jun 22 | 3,005 | 149 | 1,059 | 196 |
| 31 Mar 22 | 3,086 | 169 | 1,056 | 196 |
| 31 Dec 21 | 3,116 | 179 | 1,068 | 181 |
| 30 Sep 21 | 3,123 | 148 | 1,064 | 181 |
| 30 Jun 21 | 3,024 | 141 | 996 | 181 |
| 31 Mar 21 | 2,855 | 75 | 982 | 181 |
| 31 Dec 20 | 2,797 | -1 | 893 | 266 |
| 30 Sep 20 | 2,787 | 14 | 919 | 266 |
| 30 Jun 20 | 2,882 | 15 | 982 | 266 |
| 31 Mar 20 | 2,977 | 38 | 1,007 | 266 |
| 31 Dec 19 | 2,996 | 79 | 1,054 | 229 |
| 30 Sep 19 | 3,052 | 94 | 1,034 | 229 |
| 30 Jun 19 | 3,015 | 124 | 976 | 229 |
| 31 Mar 19 | 2,955 | 127 | 933 | 229 |
| 31 Dec 18 | 2,851 | 146 | 951 | 178 |
| 30 Sep 18 | 2,760 | 131 | 936 | 178 |
| 30 Jun 18 | 2,713 | 103 | 946 | 178 |
| 31 Mar 18 | 2,669 | 82 | 952 | 178 |
| 31 Dec 17 | 2,695 | 50 | 1,133 | 0 |
| 30 Sep 17 | 2,616 | 63 | 1,104 | 0 |
| 30 Jun 17 | 2,542 | 72 | 1,062 | 0 |
| 31 Mar 17 | 2,483 | 51 | 1,033 | 0 |
| 31 Dec 16 | 2,425 | 31 | 1,005 | 0 |
| 30 Sep 16 | 2,445 | 47 | 987 | 0 |
| 30 Jun 16 | 2,446 | 7 | 981 | 0 |
| 31 Mar 16 | 2,473 | 75 | 967 | 0 |
| 31 Dec 15 | 2,455 | 122 | 856 | 83 |
| 30 Sep 15 | 2,443 | 117 | 859 | 83 |
| 30 Jun 15 | 2,406 | 158 | 838 | 83 |
| 31 Mar 15 | 2,361 | 125 | 820 | 83 |
| 31 Dec 14 | 2,351 | 111 | 844 | 63 |
| 30 Sep 14 | 2,375 | 95 | 832 | 63 |
| 30 Jun 14 | 2,403 | 98 | 841 | 63 |
| 31 Mar 14 | 2,500 | 145 | 856 | 63 |
| 31 Dec 13 | 2,532 | 165 | 887 | 34 |
Kwaliteitswinsten: 4241 is currently unprofitable.
Groeiende winstmarge: 4241 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4241 is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Versnelling van de groei: Unable to compare 4241's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 4241 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-32.8%).
Rendement op eigen vermogen
Hoge ROE: 4241 has a negative Return on Equity (-15.76%), as it is currently unprofitable.